<table>
<thead>
<tr>
<th>Contents</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>amfAR in 2019</td>
<td>01</td>
</tr>
<tr>
<td>Grants, Fellowships, and Awards</td>
<td>09</td>
</tr>
<tr>
<td>Research Grants, Fellowships, and Awards</td>
<td></td>
</tr>
<tr>
<td>TREAT Asia Grants and Awards</td>
<td></td>
</tr>
<tr>
<td>Public Policy Awards</td>
<td></td>
</tr>
<tr>
<td>Financial Highlights</td>
<td>15</td>
</tr>
<tr>
<td>Leadership and Advisory Committees</td>
<td>17</td>
</tr>
<tr>
<td>Board of Trustees</td>
<td></td>
</tr>
<tr>
<td>Scientific Advisory Committee</td>
<td></td>
</tr>
<tr>
<td>Program Advisory Council</td>
<td></td>
</tr>
<tr>
<td>Management Group</td>
<td></td>
</tr>
</tbody>
</table>

Our Mission: amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.
Countdown to a Cure for AIDS

In 2015, amfAR launched its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure. To date, amfAR has awarded 79 Countdown grants totaling more than $48 million to support research conducted by 277 scientists working at 95 institutions in 15 countries. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following components:

1. The amfAR Institute for HIV Cure Research was established in 2015 with a $20 million grant over five years to the University of California, San Francisco (UCSF). Researchers at the Institute have been laying the groundwork for a complex clinical study employing a three-pronged approach to eradicating HIV. A therapeutic vaccine will be combined with an immune adjuvant—a drug often used to boost the efficacy of vaccines—that has been shown in clinical trials to have additional anti-HIV effects. The third component combines two broadly neutralizing antibodies, the source of much optimism in the cure field for their ability not only to kill viruses that are produced by infected cells, but also to direct the immune system to kill the cells producing those viruses.

2. Investment Grants, awarded over a four-year period, are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV. In February 2019, amfAR announced new funding to researchers using cutting-edge technology to address the main barrier to an HIV cure: the persistent reservoirs of virus not cleared by antiretroviral therapy (ART). Totaling $800,000, this new round of Investment grants launched the critical third phase of a research project begun in 2017.

In the first two phases of her study, Dr. Hui Zhang of Johns Hopkins University used mass spectrometry to scan the surface of human cells for proteins—biomarkers—that discriminate between latently infected and uninfected cells. After scanning a variety of cell lines, she identified 17 potential targets. In phase three, Dr. Zhang is teaming up with HIV scientist Dr. Weiming Yang, also of Johns Hopkins University, to determine in a preclinical study whether specifically killing cells displaying any of these 17 proteins will eliminate the latent reservoir.

3. Impact Grants of up to $2 million each over four years support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure. In September 2018, amfAR awarded grants totaling $828,000 to advance two critical areas of HIV cure research. Five grants are supporting a range of efforts to understand the mechanisms and predictors of post-treatment control, whereby a small number of individuals are able to control their HIV after stopping treatment. Three additional grantees are studying HIV-positive populations in low- and middle-income countries to look for differences in how the persistent viral reservoir forms and changes over time.

4. ARCHE, the amfAR Research Consortium on HIV Eradication, supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. In September 2018, amfAR awarded $800,000 in new ARCHE funding to six teams of researchers developing an ambitious gene therapy-
based approach to curing HIV. The award launched a critical new phase in a study initiated in 2017. In a three-pronged attack on the HIV reservoir, the researchers are employing broadly neutralizing antibodies, CAR stem cells—cells genetically reprogrammed to recognize and attack infected cells—and molecular scissors targeting the virus. The grant was supported in part by the Bill and Melinda Gates Foundation.

The investigators are: Dr. Hildegard Büning of Hannover Medical School, Germany; Dr. Keith Jerome of the University of Washington, Seattle; Dr. Hans-Peter Kiem of Fred Hutchinson Cancer Research Center, Seattle; Dr. Scott Kitchen of UCLA; Dr. Yasuhiro Takeuchi of University College London; Dr. Drew Weissman of University of Pennsylvania in Philadelphia; and Dr. Richard Wyatt of The Scripps Research Institute in La Jolla, CA.

In June 2019, amfAR awarded $1.16 million in ARCHE grants for a pair of innovative research studies pursuing different angles to attack HIV. Dr. Keith Jerome of the University of Washington, Seattle, was awarded $344,000 for a project that aims to advance a cost-effective *in vivo* gene therapy strategy for curing HIV in which gene-editing tools are injected directly into the patient using vectors that function like ‘Trojan horses.’

And Dr. Jonathan Li of Brigham and Women’s Hospital, Boston, was awarded $815,000 for a project studying post-treatment control of the virus. Dr. Li and his team are gathering and analyzing samples from a multinational cohort of post-treatment controllers to investigate whether characteristics of the virus or immunologic responses predict control. Discovering what leads to post-treatment control in some people could help to achieve durable ART-free control in all people living with HIV.

The Mathilde Krim Fellowships in Basic Biomedical Research support bright young scientists advancing innovative solutions to HIV/AIDS. In September 2018, amfAR announced the recipient of the 2018 Mathilde Krim Fellowship in Basic Biomedical Research: Dr. Yen-Ting Lai of the Vaccine Research Center/National Institutes of Health in Bethesda, MD. The 2019 Krim fellows, Dr. Maolin Lu of Yale University in New Haven, CT, and Dr. Shaheed Abdulhaqq, of Oregon Health and Science University in Portland, OR, were announced in September 2019. Each fellow is awarded approximately $150,000 over two years.

In the March 2019 issue of *Nature*, researchers affiliated with amfAR’s IciStem consortium reported on the “London patient,” who may be only the second person to have been cured of HIV following a stem cell transplant. This case—along with the “Düsseldorf patient,” who may also have been cured—is providing critical new data to compare with the case of the “Berlin patient,” the first known case of a cure.

A Family Trait

CCR5, the primary receptor enabling HIV to infect cells, is known for its role in the cure of the “Berlin patient” following a stem cell transplant with donor cells bearing a mutated CCR5 protein. In the April 2019 issue of *eLIFE*, Dr. Steven Deeks of UCSF and colleagues reported that people with a natural ability to control their HIV without ART had less CCR5 present on their cells than noncontrollers, and their cells were less permissive to HIV infection. Furthermore, natural resistance to HIV through reduced levels of CCR5 was shown to be inherited.
Identifying a Biomarker for the ‘Active’ HIV Reservoir

In the May 2019 issue of *Pathogens and Immunity*, Drs. Timothy Henrich and Peter Hunt, both at UCSF, reported on a potential biomarker of the “active reservoir”—persistent virus that is probably first to re-seed infection when ART is stopped. Thinking on the nature of the reservoir is evolving to include not only latent, but also active reservoir. Differentiating cells harboring active reservoir from healthy, uninfected cells would be an important advance.

HIV Cure Summit

In December 2018, amfAR held its fifth annual HIV Cure Summit at UCSF, where the amfAR Institute for HIV Cure Research is based. Leading amfAR-funded cure researchers detailed their progress and discussed the scientific challenges that stand in the way of a cure. Dr. Rowena Johnston, amfAR vice president and director of research, elucidated the two types of cure that researchers are pursuing: eradication and post-treatment control. In eradication, an individual completely clears HIV from his or her body, while in post-treatment control some virus remains but the immune system can control it without ART. Dr. Steven Deeks, a professor of medicine at UCSF and a lead investigator at the amfAR Institute, explained the complex clinical study he is about to embark on. The Summit also featured a range of perspectives from members of the community advisory board for the amfAR Institute and other community leaders.

Think Tanks

Consistent with amfAR’s commitment to investigate every avenue that may lead to a cure, the Foundation regularly hosts think tanks that bring together leading investigators in various fields.

In March 2019, amfAR convened experts to discuss cutting-edge approaches to curing HIV that amfAR could pursue through its gene therapy research initiative, ARCHE-GT. In May, members of amfAR’s IciStem consortium of European researchers that aims to replicate the case of “the Berlin patient” gathered for a think tank in Dublin, Ireland. And in August, amfAR hosted a think tank in New York City on the CCR5 receptor as a target in cure research. The researchers discussed ways to use CCR5 to develop a more generalizable cure than one involving risky and costly stem cell transplants.

PUBLIC POLICY

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate HIV/AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research and global HIV/AIDS programs, expand access to treatment and care for marginalized populations, advocate harm reduction policies aimed at reducing the spread of HIV and hepatitis C (HCV) among people who inject drugs, and protect the civil rights of all people affected by or vulnerable to HIV/AIDS.

Ending the Domestic HIV Epidemic

In 2019, President Trump announced a plan to end HIV transmissions in the U.S. by 2030, targeting geographic hotspots of infection. The Ending the HIV Epidemic (EHE) initiative aims to reduce HIV infections by 75% in five years, and by 90% in ten years. In 2019, amfAR launched a free interactive database (ehe.amfar.org) to help policymakers, public health officials, advocates, and other stakeholders understand the opportunities and challenges across EHE jurisdictions. The EHE database includes demographic, policy, and service provider information, and epidemiological indicators.

In 2018 the Trump administration proposed a rule change to the Title X National Family Planning Program, stating that health providers in the Title X program “may not perform, promote, refer for, or support abortion.” The stipulation is commonly known as the domestic gag rule. In February 2019, amfAR published *Title X, the Domestic Gag Rule, and the HIV Response*, an issue brief illustrating the benefits of the Title X program and potential impacts of the gag rule. Analysis from the report shows that, if implemented, the domestic gag rule could not only undermine women’s access to reproductive health services, but also impede access to HIV testing for low-income populations, threatening the national response to the HIV epidemic.

And in March 2019, amfAR published an issue brief titled *Expanding Access to Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults: Models for Addressing Consent, Confidentiality, and Payment Barriers*. Ensuring that adolescents and young adults at risk for HIV can access PrEP is a key step toward reducing the number of HIV diagnoses.

HIV and the Opioid Epidemic

amfAR’s Opioid & Heath Indicators Database (opioid.amfar.org) is a free web platform designed to support lawmakers, communities, and advocates in making informed policy decisions about the opioid epidemic and its impact on HIV and hepatitis C. It provides local to national statistics using reliable data sources on new HIV and hepatitis C infections, opioid use and overdose death rates, and the availability of services like drug treatment programs and syringe exchange.

In October 2018, amfAR published an analysis in *Health Affairs* on the low percentage of substance use facilities that test for
HIV or hepatitis C. The New York Times published several articles highlighting the bipartisan opioid bill passed by Congress that linked to amfAR's original Health Affairs analysis on the dearth of substance use treatment facilities that offer medication-assisted treatment (MAT) nationwide.

Since uptake of treatment for substance use disorder and harm reduction services at syringe services programs (SSPs) can reduce the risk of HIV and hepatitis C acquisition, access to services is critically important. In November 2018, amfAR published Getting to Services: Far, Far Away, an infographic showing how far Americans must travel to substance use clinics offering MAT and SSPs. Nearly 30% of Americans live more than ten miles from a facility providing medication-assisted treatment, and nearly 80% live more than ten miles from an SSP. According to one study, people typically do not access SSPs if they are more than ten miles from where they live.

In August 2019, amfAR Senior Policy and Medical Advisor Dr. Susan Blumenthal penned an op-ed on ThriveGlobal on the need for a strategic plan for addressing the opioid epidemic in the same vein as the national strategy developed to address HIV.

Advocating on the Global Stage

In October 2018, amfAR published a first-of-its-kind analysis quantifying indirect costs charged by organizations implementing the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Examining data from 2007 to 2016, the study found that between $1.85 billion and $4.34 billion was spent on indirect costs. The study was published in the peer-reviewed online journal PLOS One, and called for increased transparency in reporting indirect costs incurred by PEPFAR.

At the biennial HIV Research for Prevention conference in Madrid, also in October 2018, amfAR policy associate Jennifer Sherwood and colleagues presented findings from a survey used to track the impact of the Expanded Mexico City Policy on the operations and service delivery of organizations receiving assistance through PEPFAR. In 2017 the Mexico City Policy, or “global gag rule,” was reinstated and expanded to restrict non-U.S.-based or foreign NGOs from receiving American financial aid if they perform, counsel on, or refer for abortion, or advocate for its liberalization outside of limited exceptions.

In January 2019, amfAR published an issue brief reporting on disruptions in service provision due to the Expanded Mexico City Policy. Based on the survey described above, amfAR revealed that PEPFAR partners in 31 countries reported disruptions in service provision due to the policy. These findings have serious implications for reproductive health and the global HIV epidemic. amfAR subsequently produced a companion infographic titled PEPFAR Programming Disrupted by Expanded Mexico City Policy.

amfAR launched the PEPFAR Monitoring, Evaluation, and Reporting Database (mer.amfar.org) in December 2018. The database enables policymakers, public health officials, advocates, and other stakeholders to access a wide range of programmatic PEPFAR data and includes downloadable PDFs, maps, data visualizations, and district-level data. The new database complements amfAR’s existing PEPFAR database (copsdata.amfar.org), which highlights planned funding by program area, country, and organization for each year that has been publicly released. The database is designed to help PEPFAR in its efforts to increase data transparency and participation in the planning process.

In February 2019, amfAR, in conjunction with AVAC, published an issue brief titled New HIV Testing Strategies in PEPFAR COP19: Rollout and Human Rights Concerns. The brief analyzes country operational plan (COP) guidance for HIV testing and recommended policies aimed at helping to find HIV-positive people who have not been identified by other testing programs and linking them to treatment.

And in May, amfAR published a pair of infographics demonstrating the effectiveness of the Global Fund to Fight AIDS, Tuberculosis and Malaria: A Global Response to HIV Requires the Global Fund and How the Global Fund Improves PEPFAR Investments. The Global Fund and PEPFAR are the world’s largest and most effective investors in HIV treatment and prevention.

IAS 2019


amfAR Vice President and Director of Public Policy Greg Millett joined Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, at a press conference on “Translating Progress Into Success to End the AIDS Epidemic.” The press conference coincided with the release of a report with the same name, coauthored by amfAR, AVAC, and Friends of the Global Fight Against AIDS, Tuberculosis and Malaria. The report shows places across the global north and south on track to end their respective epidemics and the commonalities between them.
Mr. Millett also spoke at a journalist roundtable sponsored by AVAC, and shared the stage at a separate meeting with World Health Organization representatives and Ambassador Deborah Birx, U.S. Global AIDS Coordinator, to debate the ethics of HIV recency testing in PEPFAR programs.

The TREAT Asia HIV Observational Database (TAHOD) gathers information to inform the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD-LITE database, an extension of TAHOD, contains data from over 37,000 HIV-positive patients across 10 TREAT Asia network sites and aims to increase the scope of adult data collection by gathering a subset of core variables from all HIV-infected patients who have sought care at selected TAHOD sites.

A Global Collaboration

TREAT Asia manages the Asia-Pacific section of the International epidemiology Databases to Evaluate AIDS (leDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. In FY2019, the leDEA consortium completed STAY (Study of Transitioning Asian Youth), which documented the experience of HIV-positive young adults transitioning from pediatric to adult care.

Improving Care for Children

The TREAT Asia Pediatric HIV Observational Database is a regional pediatric HIV study set up by TREAT Asia in 2006. It was modeled on the adult database and includes data from more than 6,400 children and adolescents at 17 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.
Integrating HIV, Mental Health, and Implementation Science Research

In May 2019, the U.S. National Institutes of Health awarded a five-year, $1.4 million grant to TREAT Asia and Columbia University to establish an innovative platform for integrating HIV, mental health, and implementation science research in the Asia-Pacific region. Co-led by Dr. Annette Sohn, amfAR vice president and director of TREAT Asia, and Dr. Milton Wainberg, professor of clinical psychiatry at Columbia University and the New York State Psychiatric Institute, the CHIMERA program (Capacity development for HIV and mental health research in Asia) is nested within the IeDEA (see above) Asia-Pacific regional research network. CHIMERA will bring together stellar training faculty from academic centers and public health and development agencies, and will build on existing NIH-funded mental health research being conducted through IeDEA Asia-Pacific.

Aiding and Empowering Youth

Thirty percent of new HIV infections in the Asia-Pacific occurred in people aged 15–24 years in 2017. Continuing its commitment to helping adolescents transition to adult care, in January 2019 TREAT Asia held a think tank on young adult cohort research. In December 2018, TREAT Asia's Youth ACATA—Asia Community for AIDS Treatment and Advocacy—held a workshop in Bangkok. Focused on models of service delivery for key populations, the workshop included site visits to community-based or key population-friendly HIV service providers in Bangkok.

Expanding Access to HIV Treatment

In 2018 the World Health Organization (WHO) recommended dolutegravir (DTG)-based regimens as the preferred first-line HIV treatment for adults and adolescents. But in the Asia-Pacific region, access to DTG-based regimens remains severely limited. To accelerate DTG scale-up in the region, TREAT Asia and the Clinton Health Access Initiative organized a workshop in Bangkok in March 2019 to help networks of people living with HIV and other treatment access advocates better understand issues around DTG access and use, and coordinate future advocacy efforts. And in April 2019, Giten Khwairakpam, TREAT Asia's project manager for community and policy, led a training in Bangkok for regional community advocates around the use of DTG.

Advocating for Co-Infection Treatment Access

In June 2019, TREAT Asia held its annual regional advocacy meeting on hepatitis C, HIV, and tuberculosis treatment in Bangkok, with civil society organizations, clinical care professionals, and intellectual property experts. During the year, TREAT Asia staff also presented at several conferences on hepatitis C treatment access and partnered with civil society groups and funders on advocacy efforts.

Publications

TREAT Asia Director Dr. Annette Sohn co-authored an op-ed for Asia-Pacific Biotech News, titled “Asia-Pacific: Falling Behind in the Fight Against HIV/AIDS.” The op-ed, coauthored by a Singaporean investigator, discussed the current state of the HIV epidemic in Asia, and highlighted priority issues for the regional response.

In January 2019, TREAT Asia produced a fact sheet summarizing WHO guidelines (updated, July 2018) aimed at helping policymakers and healthcare providers in low- and middle-income countries establish hepatitis C screening, care, and treatment programs.

In addition, TREAT Asia continued to publish lay-language articles on HIV/AIDS research, policy, and community issues facing the Asia-Pacific region. The articles and educational pieces appear in the TREAT Asia Report, a bimonthly e-newsletter, and on TREAT Asia’s website, www.treatasia.org.

Conferences

At the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City in July, TREAT Asia Director Dr. Annette Sohn co-chaired a special session with former IAS President Dr. Chris Beyrer of Johns Hopkins University, called “Data leading the way: Designing responses based on the numbers.” Dr. Sohn was also a session co-chair at the International Workshop on HIV Pediatrics, which convened immediately before the conference. Giten Khwairakpam, TREAT Asia’s project manager for community and policy, co-chaired the 5th International HIV/Viral Hepatitis Co-Infection preconference.

TREAT Asia was also well represented at the fourth Asia Pacific AIDS & Co-Infections Conference (APACO), held in June 2019 in Hong Kong. Several junior investigators and Ph.D. students affiliated with the TREAT Asia network gave oral and poster presentations at the conference.

The TREAT Asia Annual Network Meeting was held in October 2018 in Bangkok, Thailand, where more than 120 adult and pediatric investigators, donors, and program partners gathered to review progress, hear about regional HIV-related policy priorities, and plan for future initiatives.
THE GMT INITIATIVE

In order to focus on its core programs, amfAR is winding down its GMT Initiative, launched in 2007. The initiative was designed to support research teams and community-based partner organizations in evaluating interventions to reduce the spread and impact of HIV among gay men, other men who have sex with men, and transgender individuals (collectively, GMT) in low- and middle-income countries.

In FY2019, amfAR continued to support its final two GMT Initiative projects. Dr. Chris Beyrer of Johns Hopkins University in Baltimore is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar. The researchers are assessing the effectiveness of HIV self-testing done in the privacy of one’s home, point-of-care CD4 testing, and the use of “peer navigators” familiar with the local health system to help the newly diagnosed access HIV treatment and care.

In Bangkok, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre aim to show how innovative technologies such as websites using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs. Working in collaboration with Adam’s Love, a web-based health platform for GMT individuals, and community organizations, the team is comparing the effectiveness of online services and support interventions with traditional clinic-based HIV services, and a hybrid model that combines elements of both strategies.

PUBLIC INFORMATION

amfAR disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences to increase awareness and knowledge of the pandemic. amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.

Educational Materials

amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, an email newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to approximately 11,000 people.

The Foundation’s websites—www.amfar.org and www.curecountdown.org—feature news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. The websites attract a combined average of 36,000 visitors per month. amfAR also creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public.

Public Policy

amfAR’s Public Information team works closely with the Public Policy Office (see above) to produce a wide range of issue briefs, facts sheets, infographics, and reports. In 2019 it also worked with an animation studio to produce a short film showcasing the features and functionality of amfAR’s Opioid & Health Indicators Database (opioid.amfar.org).

Social Media

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds content to its Facebook page, live tweets from events, and posts images, videos, news, and information on Instagram. amfAR has 73,000 likes on Facebook, more than 43,000 Twitter followers, and 164,000 Instagram followers.

Media Outreach

In FY2019, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. Articles and reports involving amfAR—many of which included interviews

**Celebrity Support**

amfAR’s public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help advance the Foundation’s mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR’s Founding International Chairman, and others have followed in her footsteps.

amfAR is profoundly grateful for the continuing support of celebrities from all over the world, including Katy Perry, Dame Shirley Bassey, Matt Bomer, Zoe Saldana, Grace Jones, Milla Jovovich, Heidi Klum, Alan Cumming, Michelle Rodriguez, Karolína Kurková, Alessandra Ambrosio, Caroline Vreeland, Candice Swanepoel, Elsa Hosk, Karen Elson, Lais Ribeiro, Victoria Justice, Winnie Harlow, Alexander Skarsgård, Pharrell Williams, Michelle Yeoh, Nicole Scherzinger, Charli XCX, Chris Tucker, Carine Roitfeld, Henry Golding, Eva Longoria, Andie MacDowell, Natasha Poly, Patricia Arquette, Antonio Banderas, Orlando Bloom, Ian Bohen, Adrien Brody, H.E.R., Tommy Hilfiger, Julian Lennon, Adriana Lima, Coco Rocha, Sara Sampaio, Christoph Waltz, Rebel Wilson, CeeLo Green, Joan Smalls, and Rita Ora.
2019 RESEARCH GRANTS, FELLOWSHIPS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2018, through September 30, 2019.

amfAR Research Consortium on HIV Eradication (ARCHE)

ATI following allogeneic SCT withdelta 32 donor tissue
Ravindra Gupta, MD, PhD
University of Cambridge
Cambridge, Cambridgeshire, UK
$45,000

Immune and viral determinants of HIV rebound
Jonathan Li, MD, MMSc
The Brigham and Women’s Hospital, Inc.
Boston, MA
$815,014

ARCHE – GENE THERAPY GRANTS

amfAR Research Consortium on HIV Eradication – Gene Therapy (ARCHE-GT): Preparation Phase
Hildegard Büning, PhD
Hannover Medical School
Hannover, Lower Saxony, Germany
$472,728

AAV transgene delivery in vivo in non-human primates
Keith Jerome, MD, PhD
University of Washington
Seattle, WA
$344,332

ARCHE Gene Therapy Phase 2: Using LNPs to deliver gene therapy to cure HIV
Drew Weissman, MD, PhD
University of Pennsylvania
Philadelphia, PA
$327,272

IMPLICATION GRANTS: GAINING INSIGHTS FROM THE CLINIC

Novel glycomic biomarkers predicting time to HIV rebound after treatment interruption
Mohamed Abdel-Mohsen, PhD
The Wistar Institute
Philadelphia, PA
$130,000

Immunological, genetic and virological analyses of HIV remission in the HEATHER cohort – the PITCH study arm
John Frater, MD, PhD, FRCP
University of Oxford
Oxford, Oxfordshire, United Kingdom
$299,342

Temporal phylogenetic characterization of the latent HIV reservoir in a cohort of virally suppressed Ugandans
Edward Nelson Kankaka, MBChB, MPH
Rakai Health Sciences Program
Kampala, Uganda
$50,000

Determinants of HIV rebound and remission
Jonathan Li, MD, MMSc
The Brigham and Women’s Hospital, Inc.
Boston, MA
$100,000

Characterization of HIV infected women that maintain without HAART sustained indetectable viral load following PMTCT
Godwin Nchinda, PhD
Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS
Yaounde, Center Region, Cameroon
$49,409

HIV persistence and antigen-specific immunity: the HIV hygiene hypothesis
Reena Rajasuriar, PhD
University of Malaya
Kuala Lumpur, Malaysia
$49,659

HIV persistence in lymph nodes in the face of ART in TB-infected individuals
Alex Sigal, PhD
Africa Health Research Institute (AHRI)
Durban, KwaZulu-Natal, South Africa
$50,000

Mechanistic and empirical modeling of viral rebound to identify predictors of post-treatment control
Rui Wang, PhD
Harvard Pilgrim Health Care Institute
Wellesley, MA
$99,810

INVESTMENT GRANTS: BRINGING BIOENGINEERS TO CURE HIV – PHASE III

Deciphering latency-associated sugar-code to detect and eliminate latent reservoir
Weiming Yang, PhD
Johns Hopkins University
Baltimore, MD
$800,000

MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH

Determination of HIV resistance mechanisms with entry inhibitors targeting the conserved receptor binding site
Yen-Ting Lai, PhD
National Institutes of Health
Bethesda, MD
$150,000

Developing a machine-learning-guided HIV immunogen design to elicit cross-reactive neutralizing antibody responses
Wen-Han Yu, PhD
Ragon Institute of MGH, MIT and Harvard
Charlestown, MA
$150,000

MATHILDE KRIM FELLOWSHIP GRANTS – PHASE II

The immunomodulatory role of plasma IgA upon Fc-mediated functions in HIV
Amy Chung, PhD
University of Melbourne
Melbourne, Victoria, Australia
$50,000

MEETINGS AND CONFERENCES

9th International Workshop on HIV Persistence During Therapy
Alain Lafeuillade, MD, PhD
University of Massachusetts Medical School
Worcester, MA
$20,000

Conference on Cell & Gene Therapy for HIV Cure
Keith Jerome, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA
$10,000
All projects listed below were awarded funding during the period October 1, 2018, through September 30, 2019.

1Supported by National Institutes of Health federal award number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute on Drug Abuse, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, and the Fogarty International Center

2Supported by National Institutes of Health federal award number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

3Supported by National Institutes of Health federal award number R21HD89859 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

4Supported by National Institutes of Health federal award number D43TW011302 funded by the Fogarty International Center and the National Institute of Mental Health

5Supported with funds provided by Life Ball

AUSTRALIA

University of New South Wales
Sydney
Matthew G. Law, PhD
IeDEA Asia-Pacific Research Collaboration: TREAT Asia HIV Observational Database & Australia HIV Observational Database $302,441

IeDEA Asia-Pacific Research Collaboration: TREAT Asia Pediatric HIV Observational Database $186,364

IeDEA Asia-Pacific Research Collaboration: Cancer Studies $69,520

AUSTRALIAN HIV RESEARCH COLLABORATION (AHOD) SITES

O’Brien Street Practice
Adelaide
William Donohue, MBBS
$1,500

Sexual Health and HIV Service In Metro North Brisbane
Diane Rowling, MBBS, MTH, F(PHM), RACP, FACSHM
$7,500

Cairns Sexual Health Service
Cairns
Darren Russell, MD
$7,500

RPA Sexual Health Clinic
Camperdown
David Templeton, PhD
$7,500

Melbourne Sexual Health Centre
Carlton
Richard Teague, MBBS (Monash Uni), FRACGP, FRACHSHM
$5,850

Monash Health - Clayton
Clayton
Ian Woolley, MBBS, FRACP
$7,500

D.A. Ellis Pty Ltd
Coffs Harbour
David Ellis, MBBS
$525

East Sydney Doctors
Darlinghurst
David Baker, MB, ChB, Dip Med (Sexual Health), DCH
$6,300

St. Vincent’s Hospital Sydney Limited
Darlinghurst
Andrew Carr, MD
$7,500

Taylor Square Private Clinic
Darlinghurst
Robert Finlayson, MBBS (Syd), DiCh
$7,425

Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program
Darwin
Manoji Gunathilake, MBBS, MD, FACCHSHM
$2,025

Gladstone Road Medical Centre
Highgate Hill
David Orth, MBBS, DipVen
$6,000
Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic
Katoomba
Eva Jackson, MBBS, FACHSHM
$2,100

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic
Kingswood
Eva Jackson, MBBS, FACHSHM
$1,950

Sexual Health and AIDS Services (SHAIDS)
Lismore
David Smith, MBBS, DipVen, FACHSHM, GraphDip, BA
$7,500

Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital
Melbourne
Jennifer Hoy, MBBS
$7,500

Sunshine Coast Hospital and Health Service
Nambour West
David Sowden, MBBS
$7,500

Northside Clinic (Vic) Pty Ltd
North Fitzroy
Richard Moore, MBBS
$7,500

Royal Perth Hospital
Perth
David Nolan, MBBS, FRACP, PhD
$6,000

Prahran Market Clinic Pty Ltd
Prahran
Norman Roth, MBBS, FACHSHM
$7,500

Holsworthy House Medical Practice
Sydney
Mark Bloch, MD
$7,500

Sydney Sexual Health Centre, Sydney Hospital
Sydney
Rick Varma, MBBS, MRCP
$6,900

Clinic 468, HNE Sexual Health, Hunter New England Local Health District
Tamworth NEMSC
Nathan Ryder, MD
$1,500

Illaawarra Shoalhaven Local Health District
Warrawong
Katherine Brown, MD
$1,650

CAMBODIA

National Center for HIV/AIDS, Dermatology & STDs / Cambodia National Institute of Public Health
Phnom Penh
Ly Penh Sun, MD, MSc
TAHOD Low Intensity Transfer (TAHOD LITE)
$9,000

TREAT Asia HIV Observational Database (TAHOD)
$20,800

TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
$25,000

CHINA

Beijing Ditan Hospital
Beijing
Fuji Zhang, MD, MSPH, PhD
TREAT Asia HIV Observational Database (TAHOD)
$8,000

TREAT Asia HIV Observational Database (TAHOD)
$20,800

Queen Elizabeth Hospital
Hong Kong
Man Po Lee, MBBS
TAHOD Low Intensity Transfer (TAHOD LITE)
$7,900

TREAT Asia HIV Observational Database (TAHOD)
$22,880

INDIA

The Voluntary Health Services
Chennai
Nagalingeswaran KumaraSamy, MD, MBBS, PhD
TAHOD Low Intensity Transfer (TAHOD LITE)
$7,500

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,880

Institute of Infectious Diseases
Pune
Sanjay Pujari, MD, AAIHVS, MBBS
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2) Pilot Study
$10,648

TAHOD Low Intensity Transfer (TAHOD LITE)
$9,600

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,880

INDONESIA

Sanglah Hospital, Udayana University School of Medicine
Denpasar
Tuti Parwati Merati, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,880

Ketut Dewi Kumara Wati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
$7,500

Cipto Mangunkusumo General Hospital
Jakarta
Nia Kurniati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
$7,500

Evy Yuniahasutri, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,192

JAPAN

National Center for Global Health and Medicine
Shinjuku
Junko Tanuma, MD, PhD
Study on pregnancy and birth outcomes among women living with HIV in Asia
$5,000

TREAT Asia HIV Observational Database (TAHOD)
$16,640

MALAYSIA

Hospital Raja Perempuan Zainab II
Kota Bharu
Nik Khairulddin Nik Yusoff, MD
TREAT Asia Pediatric HIV Observational Database (TAHOD) Site
$7,500

Hospital Likas
Kota Kinabalu
Fong Siew Moy, MBBS
TREAT Asia Pediatric HIV Observational Database (TAHOD) Site
$7,500

Pediatric Institute, Hospital Kuala Lumpur
Kuala Lumpur
Thahira Mohamed, MBBS
TREAT Asia Pediatric HIV Observational Database (TAHOD) Site
$7,500

University of Malaya Medical Center
Kuala Lumpur
Raja Iskandar Shah Raja Azwa, MBBS
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2) Pilot Study
$10,648

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,880

Sungai Buloh Hospital
Sungai Buloh
Yasmin Mohamed Gani, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,880
PHILIPPINES
Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City
Rossana Ditangco, MD
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2) Pilot Study
$10,648
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,360

SINGAPORE
Tan Tock Seng Hospital
Singapore
Oon Tek Ng, MBBS, MRCP, MMed, MPH
TREAT Asia HIV Observational Database (TAHOD) $18,200¹

SOUTH AFRICA
University of Cape Town
Mowbray
Mary-Ann Davies, MBChB, MMed, FCPHM
Global IRAmework for Data Collection Used for Adolescent HIV Transition Evaluation (GRADUATE)
$64,351³
Global IRAmework for Data Collection Used for Adolescent HIV Transition Evaluation (GRADUATE)
Supplement
$3,000³
Wits Health Consortium (Pty) Ltd
Parktown, JHB
Karl Technau, MBBCh, MSc (Med)
Global IRAmework for Data Collection Used for Adolescent HIV Transition Evaluation (GRADUATE)
$7,647³

SOUTH KOREA
Yonsei University College of Medicine
Seoul
Jun Yong Choi, MD, PhD
Study on pregnancy and birth outcomes among women living with HIV in Asia
$1,200¹
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2) Pilot Study
$10,648
TAHOD Low Intensity Transfer (TAHOD LITE)
$6,400¹
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$17,680¹

TAIWAN
Taipei Veterans General Hospital
Taipei City
Yu-Juun Chan, MD
TAHOD Low Intensity Transfer (TAHOD LITE)
$6,400¹ (year 1); $6900¹ (year 2)

THAILAND
Chulalongkorn University
Bangkok
Thanyawee Puthanakit, MD
Change of bone mineral density among perinatally HIV-infected adolescents after stopping calcium and vitamin D (CAL-D2)
$4,370¹
TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
$15,000¹
HIV-NAT / Thai Red Cross AIDS Research Centre
Bangkok
Anchalee Avihingsanon, MD, PhD
Substance use, Stigma, Depression and Disability among Adults with HIV in Asia (S2D2) Pilot Study
$10,648
TAHOD Low Intensity Transfer (TAHOD LITE)
$8,400¹
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$24,440¹
TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
$7,500

Purple Haze Company Limited
Muang Tarandeep Anand
The impact of online interventions on the HIV prevention/treatment cascade among MSM and TG individuals
$30,000

USA
Johns Hopkins University
Baltimore Vidya Mave, MD, MPH Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India (Supplement)
$45,897

Massachusetts General Hospital
Boston Andrea Ciaranello, MD, MPH Estimating the magnitude of the pediatric and adolescent HIV epidemic in Thailand
$30,000

Columbia University
New York Milton Wainberg, MD Capacity development for HIV and mental health research in Asia (CHIMERA)
$46,763

VIETNAM
Bach Mai Hospital
Hanoi Do Duy Cuong, MD, PhD TAHOD Low Intensity Transfer (TAHOD LITE) $8,400
TREAT Asia Pediatric HIV Observational Database (TApHOD) Site $20,000

National Hospital of Pediatrics
Hanoi Nguyen Van Lam, MD, MSc TREAT Asia Pediatric HIV Observational Database (TApHOD) Site $20,000

Children’s Hospital 1
Ho Chi Minh City Truong Huu Khanh, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) Site $20,000

Children’s Hospital 2
Ho Chi Minh City Do Chau Viet, MD TREAT Asia Pediatric HIV Observational Database (TApHOD) Site $20,000
## FINANCIAL HIGHLIGHTS
For the year ended September 30, 2019

### Public Support and Revenue
- Public support $4,308,007
- Special events 16,680,645
- Planned giving 2,156,596
- Government funding 6,017,798
- Investment income and other revenue 2,552,030

**Total public support and revenue** $31,715,076

### Expenses
- Research $15,365,954
- TREAT Asia 4,670,067
- GMT Initiative 268,329
- Public Policy 2,049,054
- Public Information 4,098,005

**Total program services** $26,451,409

- Fundraising 5,884,444
- Management and general 2,445,341

**Total supporting services** $8,329,785

**Total expenses** $34,781,194

### Change in net assets
- (3,066,118)

### Net assets, beginning of year
- 52,550,679

**Net assets, end of year** $49,484,561

## STATEMENT OF FINANCIAL POSITION

### Assets
- Cash and investments $51,009,360
- Pledges and receivables, net 7,207,120
- Prepaid expenses and other assets 3,139,811
- Furniture, equipment, and leasehold improvements, net 2,800,812

**Total Assets** $64,157,103

### Liabilities
- Accounts payable and accrued expenses $2,769,299
- Grants and fellowships payable, net 2,086,068
- Deferred support and refundable advances 7,947,789
- Other long-term liabilities 1,869,386

**Total liabilities** $14,672,542

**Total net assets** $49,484,561

**Total liabilities and net assets** $64,157,103
EXPENSES

Fundraising $ 5,884,444
Management and general $ 2,445,341
Program $ 26,451,409

Total $ 34,781,194

PROGRAM EXPENSES

Research $ 15,365,954
TREAT Asia $ 4,670,067
GMT Initiative $ 268,329
Public Policy $ 2,049,054
Public Information $ 4,098,005

Total $ 26,451,409
TRUSTEE EMERITUS

Arthur J. Ammann, M.D.
President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco
San Francisco, CA

Alberto Bosque, Ph.D.*
Assistant Professor
Department of Microbiology, Immunology, and Tropical Medicine
The George Washington University

IN MEMORIAM

Mathilde Krim, Ph.D.
Founding Chairman

Dame Elizabeth Taylor
Founding International Chairman

Sheldon W. Andelson, Esq.
Arnold W. Klein, M.D.
Mrs. Albert D. Lasker
Jonathan M. Mann, M.D., M.P.H.
Maxine Mesinger
Pauline Phillips
Natasha Richardson
Allan Rosenfield, M.D.
Peter Scott, Esq.
Wallace Sheff, C.P.A.
Tom Stoddard
Joel D. Weisman, D.O.

SPECIAL APPOINTMENT

Global Fundraising Chairman
Milutin Gatsby

amfAR AMBASSADORS

Cheyenne Jackson
Janet Jackson
Milla Jovovich
Liza Minnelli
Michelle Yeoh

SCIENTIFIC ADVISORY COMMITTEE

*Adjunct Member

Mohamed Abdel-Mohsen, Ph.D.*
Assistant Professor
Vaccine & Immunotherapy Center
The Wistar Institute

Maria Luisa Alcaide, M.D.*
Associate Professor of Clinical Infectious Diseases
Miller School of Medicine
University of Miami

Galit Alter, Ph.D.*
Professor of Medicine
Harvard Medical School
Ragon Institute of MGH, MIT and Harvard

Jintanat Ananworanich, M.D., Ph.D.
Associate Director for Therapeutics Research
US Military HIV Research Program

Judith Auerbach, Ph.D.*
Professor of Medicine
School of Medicine
University of California, San Francisco

* Adjunct Member

Mohamed Abdel-Mohsen, Ph.D.*
Assistant Professor
Vaccine & Immunotherapy Center
The Wistar Institute

Maria Luisa Alcaide, M.D.*
Associate Professor of Clinical Infectious Diseases
Miller School of Medicine
University of Miami

Galit Alter, Ph.D.*
Professor of Medicine
Harvard Medical School
Ragon Institute of MGH, MIT and Harvard

Jintanat Ananworanich, M.D., Ph.D.
Associate Director for Therapeutics Research
US Military HIV Research Program

Judith Auerbach, Ph.D.*
Professor of Medicine
School of Medicine
University of California, San Francisco

* Adjunct Member

Mohamed Abdel-Mohsen, Ph.D.*
Assistant Professor
Vaccine & Immunotherapy Center
The Wistar Institute

Maria Luisa Alcaide, M.D.*
Associate Professor of Clinical Infectious Diseases
Miller School of Medicine
University of Miami

Galit Alter, Ph.D.*
Professor of Medicine
Harvard Medical School
Ragon Institute of MGH, MIT and Harvard

Jintanat Ananworanich, M.D., Ph.D.
Associate Director for Therapeutics Research
US Military HIV Research Program

Judith Auerbach, Ph.D.*
Professor of Medicine
School of Medicine
University of California, San Francisco

* Adjunct Member
Bruno De Geest, Ph.D.
Chemical Engineer
Laboratory of Pharmaceutical Technology
Ghent University Hospital

Sherry Deren, Ph.D.
Co-Director
Center for Drug Use and HIV Research
New York University College of Nursing

Roger Detels, M.D., M.S.
Professor of Epidemiology
School of Public Health
University of California, Los Angeles

Carl W. Diefenbach, Ph.D.
Director
Division of AIDS (DAIDS)
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Ivan D’Orso, Ph.D.*
Associate Professor
Department of Microbiology
University of Texas Southwestern

Daniel C. Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

D. Peter Drotman, M.D., M.P.H.
Editor-in-Chief
Emerging Infectious Diseases
Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.
Director
Division of Gender, Sexuality, & Health
Program for the Study of LGBT Health
NYS Psychiatric Institute/Columbia University

Homayoon Farzadegan, Ph.D.
Professor
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

Dianne M. Finklestein, Ph.D.
Professor of Biostatistics
Harvard School of Public Health
Director of the Cancer Center Biostatics
Massachusetts General Hospital

Andrés Finzi, Ph.D.*
Associate Professor
Department of Microbiology and Immunology
Université de Montréal, Centre de Recherche du CHUM

Gerald Herbert Friedland, M.D.
Professor and Director
AIDS Care Program
Department of Internal Medicine
Yale School of Medicine

Howard E. Gendelman, M.D.
Professor and Chair, Department of Pharmacology and Experimental Neuroscience
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases
Director, Center for Neurodegenerative Disorders
University of Nebraska Medical Center

Sara Gianella Weibel, M.D.*
Assistant Professor of Medicine
CFAR - Center for AIDS Research
Department of Medicine, Division of Infectious Diseases
University of California, San Diego

Nancy L. Haigwood, Ph.D.
Director and Senior Scientist
Division of Pathobiology and Immunology
Oregon National Primate Research Center
Oregon Health and Science University

Andrew Henderson, Ph.D.*
Associate Professor
School of Medicine
Boston University

Alon Herschhorn, Ph.D.*
Assistant Professor of Medicine
Division of Infectious Diseases and International Medicine
University of Minnesota

Charles H. Hinkin, Ph.D.
Professor
Department of Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine
University of California, Los Angeles

David Ho, M.D.
Scientific Director, Chief Executive Officer
Aaron Diamond AIDS Research Center

Ya-Chi Ho, M.D., Ph.D.*
Assistant Professor of Microbial Pathogenesis and Medicine
Microbial Pathogenesis
Yale University

Thomas J. Hope, Ph.D.
Professor
Department of Cell and Molecular Biology
Feinberg School of Medicine
Northwestern University

Shiu-Lok Hu, Ph.D.
Professor
School of Pharmacy
University of Washington

Moses Joloba, M.B.Ch.B., M.S., Ph.D.*
Associate Professor
College of Health Sciences, Department of Medical Microbiology
Makerere University
School of Medicine
Case Western Reserve University

R. Brad Jones, Ph.D.*
Assistant Professor of Immunology in Medicine
Graduate School of Medical Sciences
Weil Medical College of Cornell University

Edward Kankaka, M.B.Ch.B., M.P.H.*
Rakai Health Sciences Program

Jonathan Karn, Ph.D.*
Director
Center for AIDS Research
Case Western Reserve University

Vineet KewalRamani, Ph.D.
Chief, Model Development Section
HIV Drug Resistance Program
National Cancer Institute
National Institutes of Health

Scott Kitchen, Ph.D.
Assistant Professor of Medicine
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles

Richard Kornbluth, M.D., Ph.D.
President and Chief Scientific Officer
Multimere Biotherapeutics, Inc.

Richard A. Koup, M.D.
Deputy Director, Vaccine Research Center
Chief, Immunology Laboratory
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Nathaniel R. Landau, Ph.D.
Professor
Department of Microbiology
New York University School of Medicine

Alan L. Landay, Ph.D.
Professor and Chairman
Department of Immunology and Microbiology
Rush-Presbyterian-St. Luke’s Medical Center

Michael Lederman, M.D.
Scott R. Inkley Professor of Medicine
Associate Director, Center for AIDS Research
Case Western Reserve University

Tun-Hou Lee, D.Sc.
Professor of Virology, Emeritus
Department of Immunology and Infectious Diseases
Harvard School of Public Health

Michael J. Leibowitz, M.D., Ph.D.
Professor, Medical Microbiology and Immunology
University of California, Davis

Robert J. Levine, M.D.
Professor of Medicine
Center for Interdisciplinary Research on AIDS
Yale University

Judy Lieberman, M.D., Ph.D.
Senior Investigator
Immune Disease Institute
Professor of Pediatrics
Harvard Medical School

Manuel Llano, M.D., Ph.D.*
Assistant Professor
University of Texas at El Paso

H. Kim Lyerly, M.D.
Professor in Surgery, Immunology, Pathology
George Barth Geller Chair of Cancer Research
Director of the Center of Applied Therapeutics
Duke Cancer Institute
Duke University Medical Center

Frank Maldarelli, M.D., Ph.D.
Investigator
HIV DRP Host-Virus Interaction Branch
National Cancer Institute
National Institutes of Health

David M. Margolis, M.D.
Professor of Medicine, Microbiology and Immunology, and Epidemiology
School of Medicine
University of North Carolina at Chapel Hill

Martin H. Markowitz, M.D.
Professor and Clinical Director
Aaron Diamond AIDS Research Center
Kenneth Hugh Mayer, M.D.
Infectious Disease Attending & Director of HIV
Prevention Research
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School

Joseph M. McCune, M.D., Ph.D.
Professor of Medicine
Department of Medicine
University of California, San Francisco

Donna Mildvan, M.D.
Chief, Division of Infectious Diseases
Department of Medicine
Beth Israel Medical Center

Godwin Nchinda, Ph.D.*
Professor
Senior Immunologist
Head of Vaccinology/Biobanking laboratory
Deputy Director General CIRCB
Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS

Jay A. Nelson, Ph.D.
Professor and Director
Vaccine and Gene Therapy Institute
Oregon Health and Science University

Nancy Padian, Ph.D., M.P.H.
Adjunct Professor of Epidemiology
School of Public Health
University of California, Berkeley

Savita Pawwa, M.D.
Professor of Microbiology and Immunology
Professor in Pediatrics and Medicine
Director of the Miami Center for AIDS Research
University of Miami Leonard M. Miller School of Medicine

Tristram G. Parslow, M.D., Ph.D.
William Patterson Timmie Professor and Chair
Department of Pathology and Laboratory Medicine
Emory University School of Medicine

Matija Peterlin, M.D.
Professor of Medicine, Microbiology and Immunology
Department of Medicine
University of California, San Francisco

Lynn Pulliam, Ph.D.
Professor
Department of Laboratory Medicine and Medicine
University of California, San Francisco
Veterans Affairs Medical Center

Reena Rajasuriar, Ph.D.*
Pharmacy Lecturer
University of Malaya

Lee Ratner, M.D., Ph.D.
Professor
Department of Medicine
Washington University School of Medicine

Andrew Rice, Ph.D.
Professor
Department of Molecular Virology and Microbiology
Baylor College of Medicine

Nadia Roan, Ph.D.*
Associate Professor
Department of Urology
University of California, San Francisco

Melissa Robbiani, Ph.D.
Senior Scientist and Director of Biomedical HIV Research
Center for Biomedical Research
Population Council

Ruth M. Ruprecht, M.D., Ph.D.
Scientist, Department of Virology and Immunology
Southwest National Primate Research Center
Director, Texas Biomed AIDS Research Program
Texas Biomedical Research Institute

Joshua Schiffer, M.D.*
Associate Member
Vaccine and Infectious Disease Division
Associate Member
Clinical Research Division
Fred Hutchinson Cancer Research Center

Frederick A. Schmitt, Ph.D.
Professor
Departments of Neurology, Psychiatry, and Psychology and Behavioral Science
Sanders Brown Center on Aging
University of Kentucky

Gerald Schochetman, Ph.D.
Senior Director
Diagnostics Research
Abbott Laboratories

Alex Sigal, Ph.D.*
Group Leader, Max Planck Institute for Infection Biology
Africa Health Research Institute (AHRI)

Viviana Simon, M.D., Ph.D.*
Professor
Department of Microbiology
Department of Medicine, Infectious Diseases
Icahn School of Medicine at Mount Sinai

Gail Skowron, M.D.
Professor of Medicine
Boston University School of Medicine

Leonidas Stamatos, Ph.D.
Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Immunology and Vaccine Development Program

Spyridon Stavrou, Ph.D.*
Assistant Professor
Department of Microbiology and Immunology
Jacobs School of Medicine & Biomedical Sciences
State University of New York at Buffalo

Kathryn Stephenson, M.D.*
Assistant Professor of Medicine
Department of Medicine
Beth Israel Deaconess Medical Center

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of Medicine

Lydie Trautmann, Eng.D., Ph.D.*
Chief
Cellular Immunology Section
U.S. Military HIV Research Program

Barbara Visscher, M.D., Dr.P.H.
Professor of Epidemiology
University of California, Los Angeles

David Vlahov, Ph.D., R.N.
Professor of Nursing,
Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.
Professor of Medicine and Pathology
Icahn School of Medicine at Mount Sinai
Director of Molecular Virology Laboratory
Department of Medicine
Mount Sinai St. Luke's and Roosevelt Hospitals

Misaki Wayengera, M.B.Ch.B., M.Sc.
Immunology, Ph.D.*
Department of Pathology
College of Health Sciences
Makerere University

Steven S. Witkin, Ph.D.
Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.
Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles
Sub-Investigator
Ruane Clinical Research

Kim Woodrow, Ph.D.*
Associate Professor
Department of Bioengineering
University of Washington

Richard T. Wyatt, Ph.D.
Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

PROGRAM ADVISORY COUNCIL

Mervyn F. Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates
Crockett, CA

Judith D. Auerbach, Ph.D.
Science and Policy Consultant, and Professor
School of Medicine
University of California, San Francisco

David Bloom, Ph.D.
Clarence James Gamble Professor of Economics and Demography
Department of Global Health and Population
Harvard T.H. Chan School of Public Health
Boston, MA